Carcinoembryonic Antigen (CEA) and Hepatic Metastasis in Colorectal Cancer: Update on Biomarker for Clinical and Biotechnological Approaches.
Carcinoembryonic Antigen (CEA) and Hepatic Metastasis in Colorectal Cancer: Update on Biomarker for Clinical and Biotechnological Approaches.
复制标题
DOI：
10.2174/1872208312666180731104244
复制
发表时间：
2018-01-01
影响因子：
--
通讯作者：
de Fatima Menezes Almeida Santos, Maria
中科院分区：
文献类型：
--
作者：
Campos-da-Paz, Mariana;Dorea, Jose Garrofe;de Fatima Menezes Almeida Santos, Maria
背景：癌胚抗原（CEA）是结直肠癌（CRC）中推荐的预后标志物，用于肿瘤诊断和监测对治疗的反应。高CEA水平与结直肠癌的进展特别相关，预计手术治疗后该标志物水平的升高会下降。由于其在结直肠癌中的作用，CEA也被探索作为癌症治疗和诊断方法的靶点。目的：这项工作的目的是强调CEA在结直肠癌进展和肝转移中的作用，以及它作为临床和生物技术方法的生物标志物的潜力。方法：检索电子医学和专利数据库Pubmed、Scopus、Science Direct、谷歌patents、Esp@cenet和美国专利商标局（USPTO）的文献。我们收集了近期出版物的相关信息，包括81篇文章和13项专利，涉及不同的CEA靶向生物技术方法用于结直肠癌的治疗和诊断。结果：CEA可通过多种途径增强结直肠癌的转移潜能。CEA除了被认为是促血管生成分子外，还能保护转移细胞免于死亡，改变窦微环境，促进粘附分子的表达和恶性细胞的存活。此外，CEA还被评价为药物传递系统、光动力治疗、放射免疫治疗、癌症成像和纳米技术设备的靶点，导致许多与开发抗CEA抗体或其片段有关的专利，这些抗体或片段有可能靶向结直肠癌和肝转移细胞。结论：CEA已在临床上用于监测结直肠癌患者，是一种具有多种生物技术应用前景的靶向生物标志物。据我们所知，这是第一份关于CEA涉及专利数据库的报告。
BACKGROUND: Carcinoembryonic Antigen (CEA) is a recommended prognostic marker in Colorectal Cancer (CRC) for tumor diagnosis and monitoring response to therapy. High CEA levels are specifically associated with CRC progression and increased levels of the marker are expected to fall following surgical treatment. Due to its role in CRC, CEA has also been explored as a target for cancer therapy and diagnosis approaches.OBJECTIVE: The goal of this work is to highlight the role of CEA in CRC progression and liver metastasis as well as its potential as a biomarker for clinical and biotechnological approaches.METHOD: A literature search of electronic medical and patent databases Pubmed, Scopus, and Science Direct, Google patents, Esp@cenet and United States Patent and Trademark Office (USPTO), was performed. Information was collected in recent publications, including 81 articles besides 13 patents related to different CEA targeting biotechnological approaches for CRC therapy and diagnosis.RESULTS: CEA enhances CRC metastatic potential through many ways. CEA protects metastatic cells from death, changes the microenvironment of sinusoids, promoting the expression of adhesion molecule and malignant cell survival, besides being considered a proangiogenic molecule. Furthermore CEA has also been evaluated as a target in drug delivery systems, photodynamic therapy, radioimmunotherapy, cancer imaging and nanotechnological devices, leading to many patents concerning to development of anti-CEA antibodies or their fragments with potential to target colorectal cancer and liver metastasis cells.CONCLUSION: CEA is already clinically used to monitor CRC patients, and it is a very promising targeting biomarker for multiple biotechnological applications. As far as we know this is the first report on CEA that addresses patents database.